N/A

All

Market Indices

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Press /

Press /

ASX Indices

Stock Scans

Commodities

Popular Pages

Plans & Portfolios

Home/News/Healthcare

Healthcare

More Articles

ASX healthcare hammered! Where’s the bottom for CSL, COH, RMD and TLX?

ASX healthcare hammered! Where’s the bottom for CSL, COH, RMD and TLX?

Carl Capolingua·

29 July

Why CSL is rallying like a growth stock again

Why CSL is rallying like a growth stock again

7 July

Healthcare stocks are bouncing. Is it time to give CSL and Cochlear a second chance?

Healthcare stocks are bouncing. Is it time to give CSL and Cochlear a second chance?

30 June

Monash IVF downgrades FY26 profit again as industry volumes fall

Monash IVF downgrades FY26 profit again as industry volumes fall

12 June

Is CSL the ASX’s biggest ever blue chip disaster? How the model is broken

Is CSL the ASX’s biggest ever blue chip disaster? How the model is broken

Carl Capolingua·

11 May

Cochlear crashes to decade low on guidance cut, worst selloff on record

Cochlear crashes to decade low on guidance cut, worst selloff on record

22 April

Immutep crashes 90% as Phase III lung cancer trial discontinued

Immutep crashes 90% as Phase III lung cancer trial discontinued

Warren Masilamony·

13 March

ResMed’s Q2 margins keep climbing, while valuation sits below history

ResMed’s Q2 margins keep climbing, while valuation sits below history

Warren Masilamony·

30 January

CSL crashes to six-year low after slashing FY26-28 growth outlook. Here's what you need to know

CSL crashes to six-year low after slashing FY26-28 growth outlook. Here's what you need to know

28 October 2025

Pro Medicus hits all-time highs. Here's what's driving the record move

Pro Medicus hits all-time highs. Here's what's driving the record move

3 July 2025

How do CSL, ResMed, Cochlear and Ansell fare against Trump tariffs?

How do CSL, ResMed, Cochlear and Ansell fare against Trump tariffs?

15 April 2025

Is Pro Medicus a bargain at $200?

Is Pro Medicus a bargain at $200?

28 March 2025

Should you buy the dip on ASX healthcare stocks CSL, Cochlear and Pro Medicus?

Should you buy the dip on ASX healthcare stocks CSL, Cochlear and Pro Medicus?

Carl Capolingua·

17 February 2025

Has CSL lost its shine as the market's favourite growth story?

Has CSL lost its shine as the market's favourite growth story?

13 February 2025

ASX growth stocks: Can Pro Medicus continue its parabolic run?

ASX growth stocks: Can Pro Medicus continue its parabolic run?

10 January 2025

CSL shares have gone nowhere for four years – Is there any value in the stock right now?

CSL shares have gone nowhere for four years – Is there any value in the stock right now?

27 November 2024

Can a debt-free Healius return to growth and resume paying dividends?

Can a debt-free Healius return to growth and resume paying dividends?

23 September 2024

ResMed shares hit 10-month highs on earnings beat, weight-loss drug tailwinds

ResMed shares hit 10-month highs on earnings beat, weight-loss drug tailwinds

29 April 2024

ResMed caught between two narratives: Bearish sleep apnea data and bullish analysts

ResMed caught between two narratives: Bearish sleep apnea data and bullish analysts

18 April 2024

The stocks to watch as the healthcare sector recovers

The stocks to watch as the healthcare sector recovers

20 February 2024

Latest News

Evening Wrap: ASX 200 slumps on mining and gold routs as investors switch to WTC, XRO and tech stocks

Reporting season masterclass! What quarterly, half-year and full-year reports really tell investors

Technical Analysis

ChartWatch ASX Scans: ANZ, Cochlear, Suncorp, IDP Education, Global X AI Infrastructure ETF, Bravura Solutions, Iress

Morning Wrap: ASX 200 to fall, S&P 500 notches record close, Tech and software stocks set to rally

All Categories

Capital Raising

Communication Services

Consumer cyclical

Consumer Discretionary

Consumer Staple

Consumer Staples

Director Transactions

Earnings Highlights

Financial Services

Insights & Opinion

Precious Metals

Reporting Season

Technical Analysis

Weekend Newsletter

Advertisement

ASX INDICES

All ASX Indices

COMMODITIES

All Commodities

INVESTMENT SCANS

Highest Dividend Yield

Broker Consensus

POPULAR PAGES

List of ASX Companies

Upcoming Dividends

Director Transactions

ASX Short Sale Data

ASX Announcements

Australian Dollar

NEWS

Editorial Process

STATS & DOWNLOADS

Market Statistics

RESOURCES

History of the ASX

EDITORS PICKS

How to Buy Shares in Australia

Dividend Yield Basics

The Basics of Franking Credits

Top 10 Investment Movies & Documentaries

OUR NETWORK

Livewire Markets

About Us Careers Privacy FSG Terms Of Use Contact Us

Market Index and its data suppliers accept no responsibility for any claim, loss or damage whatsoever as a result of information on this website or services. The Market Index website is owned by FinTech Equity Pty Ltd (ACN: 637 943 803) AFSL #521588 Factual Information Only: The Market Index website and all content, advertisements and other material contained on our website is factual information only. We are not financial advisers and none of the content on our website should be interpreted as financial advice. Nothing on our website is intended to imply a recommendation or opinion about a financial product or class of financial products. Before you make an investment decision based on any of the information contained on our website, please consult a qualified financial adviser or stockbroker. All content is provided “as is” and not intended for trading purposes.

Copyright © 2026 Market Index